

# 09 - References

## References

### Schizophrenia and related psychoses CHAPTER 1 References

1. Dudley K, et al. Chlorpromazine dose for people with schizophrenia. *Cochrane Database Syst Rev* 2017; 4(4):CD007778.
2. McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis. *J Clin Psychiatry* 1999; 60:794-795.
3. Schooler N, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry* 2005; 162:947-953.
4. Donnelly L, et al. Haloperidol dose for the acute phase of schizophrenia. *Cochrane Database Syst Rev* 2013; (8):CD001951.
5. Oosthuizen P, et al. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. *Int J Neuropsychopharmacol* 2004; 7:125-131.
6. Leucht S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. *Schizophr Bull* 2014; 40:314-326.
7. Soares BG, et al. Sulpiride for schizophrenia. *Cochrane Database Syst Rev* 2000; (2):CD001162.
8. Armenteros JL, et al. Antipsychotics in early onset schizophrenia: systematic review and meta-analysis. *Eur Child Adolesc Psychiatry* 2006; 15:141-148.
9. Koch K, et al. Trifluoperazine versus placebo for schizophrenia. *Cochrane Database Syst Rev* 2014; (1):CD010226.
10. Sparshatt A, et al. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. *Acta Psychiatr Scand* 2009; 120:416-428.
11. Buchanan RW, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010; 36:71-93.
12. Cutler AJ, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. *CNS Spectr* 2006; 11:691-702.
13. Mace S, et al. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. *CNS Drugs* 2008; 23:773-780.
14. Sparshatt A, et al. A systematic review of aripiprazole: dose, plasma concentration, receptor occupancy and response: implications for therapeutic drug monitoring. *J Clin Psychiatry* 2010; 71:1447-1456.
15. Liu CC, et al. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. *J Clin Psychopharmacol* 2013; 33:18-23.

16. Leucht S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. *Am J Psychiatry* 2020; 177:342-353.
17. Citrome L. Role of sublingual asenapine in treatment of schizophrenia. *Neuropsychiatr Dis Treat* 2011; 7:325-339.
18. Tenjin T, et al. Profile of blonanserin for the treatment of schizophrenia. *Neuropsychiatr Dis Treat* 2013; 9:587-594.
19. Correll CU, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo- controlled studies. *Schizophr Res* 2016; 174:82-92.
20. Antoun Reyad A, et al. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials. *Int Clin Psychopharmacol* 2020; 35:119-128.
21. Garnock-Jones KP. Cariprazine: a review in schizophrenia. *CNS Drugs* 2017; 31:513-525.
22. Citrome L. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. *Neuropsychiatr Dis Treat* 2018; 14:2563-2577.
23. Lokshin P, et al. Clotiapine: an old neuroleptic with possible clozapine-like properties. *Progr Neuro Psychopharmacol Biol Psychiatry* 1998; 22:1289-1293.
24. Lyseng-Williamson K. Clotiapine in schizophrenia: a guide to its use. *Drugs Ther Perspect* 2015; 31:365-371.
25. Crabtree BL, et al. Iloperidone for the management of adults with schizophrenia. *Clin Ther* 2011; 33:330-345.
26. Peng H, et al. Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis. *Int J Neuropsychopharmacol* 2024; 27:pyae052.
27. Meltzer HY, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry* 2011; 168:957-967.
28. Sanger TM, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. *Am J Psychiatry* 1999; 156:79-87.
29. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. *Int Clin Psychopharmacol* 1998; 13:253-262.
30. Keefe RS, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. *Biol Psychiatry* 2006; 59:97-105.
31. Bishara D, et al. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. *J Clin Psychopharmacol* 2013; 33:329-335.
32. Mathis MV, et al. The US Food and Drug Administration's perspective on the new antipsychotic pimavanserin. *J Clin Psychiatry* 2017; 78:e668-e673.
33. Ballard C, et al. Pimavanserin in Alzheimer's disease psychosis: efficacy in patients with more pronounced psychotic symptoms. *J Prev Alzheimers Dis* 2019; 6:27-33.
34. Nasrallah HA, et al. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. *Schizophr Res* 2019; 208:217-220.
35. Sparshatt A, et al. Quetiapine: dose-response relationship in schizophrenia. *CNS Drugs* 2008; 22:49-68.

36. Sparshatt A, et al. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. *J Clin Psychiatry* 2011; 72:1108-1123.
37. Pagsberg AK, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. *Lancet Psychiatry* 2017; 4:605-618.

10 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1

38. Terao I, et al. Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: a systematic review and dose- response model-based network meta-analysis. *J Psychopharmacol* 2023; 37:953-959.
39. Lane HY, et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. *J Clin Psychiatry* 2000; 61:209-214.
40. Williams R. Optimal dosing with risperidone: updated recommendations. *J Clin Psychiatry* 2001; 62:282-289.
41. Ezewuzie N, et al. Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. *J Psychopharmacol* 2006; 20:86-90.
42. Li C, et al. Risperidone dose for schizophrenia. *Cochrane Database Syst Rev* 2009; (4):CD007474.
43. Kaul I, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. *Lancet* 2024; 403:160-170.
44. Kaul I, et al. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5--week, randomized, double-blind, placebo-controlled, EMERGENT trials. *Schizophrenia (Heidelb)* 2024; 10:102.
45. Bagnall A, et al. Ziprasidone for schizophrenia and severe mental illness. *Cochrane Database Syst Rev* 2000; (4):CD001945.
46. Taylor D. Ziprasidone: an atypical antipsychotic. *Pharmaceutical J* 2001; 266:396401.
47. Joyce AT, et al. Effect of initial ziprasidone dose on length of therapy in schizophrenia. *Schizophr Res* 2006; 83:285-292.

---

Revision #1

Created 2026-01-04 20:12:31 UTC by Omar Ayman

Updated 2026-01-04 20:12:31 UTC by Omar Ayman